현재가
목표 주가
애널리스트 평가
5 평가: 매수
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical nee...|
e.g. Promoter holding
Loading chart...
애널리스트 컨센서스 기준 EPS 및 매출 전망.
| Metric (B) | FY 2024 | FY 2024 | FY 2025 | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2027 | FY 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | $-3.23 | $-2.64 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | |
| — | — | — | — | — | — | — | — | — | -45.0% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TCara Thera... | TVRD | $15.74M | — | 1.87 | — | — | -126.20% | — |
| 2. | GGRI Bio | GRI | $3.72M | — | 0.37 | — | — | -142.00% | — |
| 3. | EInvizyne T... | EXOZ | $35.64M | — | 9.75 | — | — | -187.20% | — |
| 4. | KKairos Pha... | KAPA | $1.54M | — | 0.37 | — | — | -114.00% | — |
| 5. | KKairos Pha... | KAPA | $1.54M | — | 0.37 | — | — | -114.00% | — |
연결 기준 (백만 단위) / 별도 보기 가능
| Quarter (M) | Dec 25 | Jun 26 |
|---|---|---|
Revenue | 1.36 | 1.4 |
COGS | 2.59 | 1.24 |
Gross Profit | -1.23 | 0.16 |
Gross Profit % | -90.3% | 11.6% |
| 29.31 | 40.08 | |
EBIT | -30.54 | -39.91 |
OPM % | -2245.03% | -2847.23% |
Non-Operating Income | -1.52 | 10.72 |
PBT | -32.06 | -29.19 |
Income Tax | -4.33 | -0.19 |
Tax Rate % | 13.52% | 0.66% |
Net Income | -26.47 | -28.58 |
NPM % | -1946.2% | -2038.83% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|
Revenue | 0.01 | 0.29 | 0.3 | 3.63 | 2.71 |
COGS | 0 | 0 | 0 | 3.59 | 4.81 |
Gross Profit | 0.01 | 0.29 | 0.3 | 0.04 | -2.1 |
Gross Profit % | 100% | 100% | 100% | 1.08% | -77.67% |
| 19.93 | 34.8 | 36.92 | 38.21 | 64.73 | |
EBIT | -19.92 | -34.51 | -36.62 | -38.17 | -66.84 |
OPM % | -225527.71% | -11803.33% | -12238.44% | -1050.63% | -2468.62% |
Non-Operating Income | -10.38 | -0.07 | -11.23 | -0.07 | 11.18 |
PBT | -30.29 | -34.57 | -47.85 | -38.24 | -55.65 |
Income Tax | 0.04 | 0.04 | 0.1 | 0.1 | -0.05 |
Tax Rate % | -0.15% | -0.11% | -0.2% | -0.27% | 0.1% |
Net Income | -30.34 | -34.61 | -47.95 | -38.34 | -53.94 |
NPM % | -343550.89% | -11838.59% | -16024.28% | -1055.27% | -1992.46% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|
| 26.98 | 11.7 | 18.58 | 29.12 | 4.14 | |
| 0 | 0 | 0.04 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.29 | 4.6 | 4.27 | 10.74 | 17.79 | |
| 56.12 | 58.65 | 49.15 | 46.63 | 38.21 | |
Total Assets | 83.38 | 74.95 | 72.04 | 86.48 | 60.14 |
| 86.76 | 97.23 | 100.68 | 176.56 | 209.95 | |
| -23.8 | -52.85 | -72.56 | -131.77 | -185.26 | |
| 0 | 0 | 0 | 0 | 0 | |
| 7.88 | 13.23 | 17.58 | 13.21 | 18.9 | |
| 12.54 | 16.14 | 27.11 | 30.4 | 18.91 | |
Total Liabilities | 83.38 | 73.75 | 72.81 | 88.4 | 62.5 |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
| 0 | -9.92 | -23.2 | -22.98 | -36.65 | -51.63 | |
| 0 | -28.37 | -1.53 | -0.32 | 1.77 | -5.3 | |
| 0 | 65.11 | 9.22 | 30.2 | 45.43 | 32.65 | |
Net CFNet Cash Flow | 0 | 26.82 | -15.51 | 6.9 | 10.56 | -24.29 |
FCFFree Cash Flow | 0 | -38.25 | -24.73 | -22.98 | -36.65 | -103.26 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|
| - | -64.5% | -132.3% | -105.2% | -155.3% | |
| - | - | - | - | - | |
| 3.46 | 1.23 | 1.30 | 2.67 | 1.16 | |
| - | 0.00 | 0.00 | 0.05 | 0.04 | |
Cash Conversion | 0.33 | 0.67 | 0.48 | 0.96 | 0.96 |
Payout Ratio | - | - | - | - | - |
| - | 3210.6% | 2.3% | 1114.3% | -25.5% | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| 3.00 | 3.00 | 4.00 | 5.00 | 3.00 | |
| - | 26.76 | -5.05 | 55.70 | -1.96 | |
| 50.00 | 50.00 | 50.00 | 0.00 | 0.00 | |
| -3435.5% | -118.4% | -160.2% | -10.6% | -19.9% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Radiopharm Theranostics Ltd의 주주 구성 (SEC 공시 기준)
이 회사의 SEC 지분 공시가 아직 없습니다.
Radiopharm Theranostics Ltd의 SEC 공시 및 실적 발표 컨퍼런스콜 녹취록
이 회사의 SEC 공시가 아직 없습니다.
What recent news says about Radiopharm Theranostics Ltd, scored for sentiment.